Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant Glioma

This study has been completed.
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Duke University
ClinicalTrials.gov Identifier:
NCT00387933
First received: October 12, 2006
Last updated: October 11, 2015
Last verified: November 2012